

21st January 2023

<b>The BSE Limited</b> 1st floor, New Trading Ring Rotunda Bldg, P.J Towers Dalal Street, Mumbai -400 001. <b>Script Code: 500259</b>	<b>The National Stock Exchange of India Limited</b> Exchange Plaza, 5 <sup>th</sup> Floor Plot No. C/1, G. Block Bandra Kurla Complex Bandra (East), Mumbai - 400 051. <b>Script Code: LYKALABS</b>
--	--

Dear Sir/ Madam,

**Sub.: Outcome of the Board Meeting held on 21st January 2023**

In Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015; this is to inform you that the Board of Directors at its Meeting held today i.e.21st January 2023 *inter alia* transacted the following;

**1. Issue of Equity Shares and Warrants convertible into Equity Shares on preferential basis to Promoter Group**

The Board has approved the raising of funds upto Rs. 100 Crores by issuing, offering and allotting the following securities of the Company to Ipca Laboratories Limited ('Promoter Group') by way of preferential issue:

- Upto 20,00,000 Equity Shares of Face value of Rs. 10/- each for cash at a price of Rs. 139.50 per Equity Share, including premium of Rs. 129.50 per Equity Share; and
- Upto 50,00,000 convertible warrants with right to the warrant holder to apply for and be allotted One (1) Equity Shares of Face value of Rs. 10/- each of the Company for each Warrants within period of Eighteen (18) months from the date of allotment of warrants at the price of Rs. 139.50 per warrant each convertible into or exchangeable for 1 (one) Equity Share of face value of Rs. 10/- each at premium of Rs. 129.50 per Equity Share.

The information pursuant to Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, is enclosed as Annexure-1.

**2. Convening of Extra Ordinary General Meeting (EOGM) of the Company**

The Board of Directors has decided to convey an EOGM on Friday, 17th February 2023 at 11 a.m. through Video Conferencing (VC)/Other Video Visual Means (OAVM), to seek the approval of shareholders of the Company for the matter specified above and has approved draft Notice of EOGM along with explanatory statement thereto.

The meeting of the Board of Directors commenced at 11 a.m. and concluded at 12: 20 p.m.

We request to take the same on your record.

Thanking You,  
Yours sincerely,

For Lyka Labs Limited

**Kishore P. Shah**  
Company Secretary & Compliance Officer  
Encl.: A/a.

## ANNEXURE 1

### DETAILS REGARDING PREFERENTIAL ISSUE

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sl.	PARTICULARS	DESCRIPTION																
1.	Type of securities proposed to be issued.	1. Equity Shares 2. Warrants Convertible into Equity Shares																
2.	Type of issuance	Preferential Allotment																
3.	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)	1. Upto 20,00,000 Equity Shares of Face value of Rs. 10/- each for cash at a price of Rs. 139.50 per Equity Share, including premium of Rs. 129.50 per Equity Share, aggregating amount upto Rs. 27.90 Crores  2. Upto 50,00,000 convertible warrants with right to the warrant holder to apply for and be allotted One (1) Equity Shares of Face value of Rs. 10/- each of the Company for each Warrants within period of Eighteen (18) months from the date of allotment of warrants at the price of Rs. 139.50 per warrant each convertible into or exchangeable for 1 (one) Equity Share of face value of Rs. 10/- each at premium of Rs. 129.50 per Equity Share, aggregating amount upto Rs.69.75 Crores																
4.	Additional details in case of Preferential Issue																	
	i. Name of the Investor	Ipca Laboratories Limited																
	ii. Post allotment of securities - outcome of the subscription, issue price / allotted price (in case of convertibles), number of investors	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th colspan="2" style="text-align: center;">Pre-issue</th> <th colspan="2" style="text-align: center;">Post Issue</th> </tr> <tr> <th style="text-align: center;">Shares</th> <th style="text-align: center;">%</th> <th style="text-align: center;">Shares</th> <th style="text-align: center;">%</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">76,24,923</td> <td style="text-align: center;">26.58</td> <td style="text-align: center;">1,46,24,923</td> <td style="text-align: center;">40.98</td> </tr> <tr> <td style="text-align: center;">76,24,923</td> <td style="text-align: center;">26.58</td> <td style="text-align: center;">1,46,24,923</td> <td style="text-align: center;">40.98</td> </tr> </tbody> </table>	Pre-issue		Post Issue		Shares	%	Shares	%	76,24,923	26.58	1,46,24,923	40.98	76,24,923	26.58	1,46,24,923	40.98
Pre-issue		Post Issue																
Shares	%	Shares	%															
76,24,923	26.58	1,46,24,923	40.98															
76,24,923	26.58	1,46,24,923	40.98															
	iii. In case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument	The Warrants proposed to be issued would be convertible into Equity Shares in one or more tranches, at the option of the proposed allottee, within a period of 18 months of its allotment																
5.	Any cancellation or termination of proposal for issuance of securities including reasons thereof	Not Applicable																